← All organizations

Samsung

For profitWebsite ↗

Also known as: Samsung Bioepis Co., Ltd. | SAMSUNG BIOEPIS CO LTD | Samsung Electronics | Samsung Pharmaceutical Co., Ltd.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

Last known activity

Feb 13, 2025

Timeline

1930s

Mar 1, 1938
Samsung— Founded

2010s

Apr 21, 2017
infliximab— Marketing Organization
Apr 21, 2017
infliximab— NDA Secondary Org

Drugs by trial phase (23 distinct, 33 trials)

Phase 4 (7 own, 0 via acquisition)

Phase 3 (13 own, 0 via acquisition)

Phase 1 (1 own, 0 via acquisition)

ulinastatin

Other trials (2 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (9)

Recent trials (34)

NCT06348199Lead sponsorPhase 3Mar 12, 2024
NCT06268613Lead sponsorPhase 1Jan 16, 2024
NCT06176963Lead sponsorPhase 2Nov 21, 2023
NCT05510063Lead sponsorPhase 4Aug 4, 2022
NCT05036005CollaboratorPhase 4Jul 11, 2021
NCT04967508Lead sponsorPhase 3Jul 6, 2021
NCT04772274Lead sponsorPhase 1Feb 4, 2021
NCT04664959Lead sponsorPhase 3Nov 26, 2020
NCT04621318Lead sponsorPhase 1Oct 19, 2020
NCT04514796Lead sponsorPhase 1Aug 12, 2020
NCT04450329Lead sponsorPhase 3Jun 23, 2020
NCT04058158Lead sponsorPhase 3Aug 31, 2019
NCT03813771CollaboratorPhase 4Mar 31, 2019
NCT03722329Lead sponsorPhase 1Nov 13, 2018
NCT03630627Lead sponsorPhase 1Aug 21, 2018

Details

Founded: Seoul, KR Mar 1, 1938
Last known activity: Feb 13, 2025